HIKAL Annual Report is a must read for everyone tracking the CDMO/API/Intermediates industry.
HIKAL being a hybrid player, their Annual Report insights on Pharma, Animal Health and Crop
More from Saket Reddy
JUBLFOOD
Double Top Buy & T20 Pattern - Bullish above 4058.33 daily close on 1% Box Size chart. https://t.co/DPEehZwkS4
Double Top Buy & T20 Pattern - Bullish above 4058.33 daily close on 1% Box Size chart. https://t.co/DPEehZwkS4
JUBLFOOD
— Saket Reddy (@saketreddy) June 24, 2020
Achieved the second target of 1820 today, now near the first target of 1780!
Got a nice 15-20% move till now.
Trailing stop loss is the best thing one can do now! https://t.co/YidPZamyxz
More from Hikal
Key insights from Hikal
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
Hikal: Strong
— JST Investments (@JstInvestments) August 5, 2021
\U0001f9ea Rev up 27% YoY
\U0001f9ea 22% EBITDA margin
\U0001f9ea Pat of 50crs
\U0001f9ea Growth across both pharmaceuticals & crop protection.#Q1withJST #Pharma pic.twitter.com/8lFo68KzPe